ESMO News

ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership

noreply@esmo.org — Tue, 01 Sep 2026 13:09:00 +00:00

ESMO has announced the recipients of the 2026 ESMO Society Awards

ESMO Announces 2026 Fellowship Recipients Supporting Innovation in Cancer Research, Artificial Intelligence and Digital Pathology

noreply@esmo.org — Tue, 01 Sep 2026 10:09:00 +00:00

ESMO has announced the recipients of its 2026 Fellowship Programme, recognising and supporting 31 oncology professionals driving innovation in cancer research, artificial intelligence, digital pathology and translational science

First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate OS Benefit in Patients with Advanced Oesophageal Squamous Cell Carcinoma

noreply@esmo.org — Tue, 01 Sep 2026 07:09:00 +00:00

Findings from the 5-year follow-up of the CheckMate 648 study

Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC

noreply@esmo.org — Mon, 31 Aug 2026 07:08:00 +00:00

Findings from the third pre-specified interim analysis of the OlympiA study

New Translations of the ESMO Patient Guides Available in Estonian

noreply@esmo.org — Fri, 28 Aug 2026 07:08:00 +00:00

Translations in the Estonian Language of the Patient Guides on Bone Health in Cancer, Immunotherapy Side-Effects and Their Management, as well as on Survivorship are provided by North Estonia Medical Centre in Tallinn

Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe

noreply@esmo.org — Fri, 28 Aug 2026 07:08:00 +00:00

Financing pan-European cancer research projects under Horizon Europe and the EU’s Multiannual Financial Framework (MFF) is essential to drive therapeutic innovation in oncology, support the development of novel cancer therapies, and deliver tangible benefits for patients with cancer.

EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide

noreply@esmo.org — Fri, 28 Aug 2026 07:08:00 +00:00

It was intended for PET imaging of somatostatin receptor overexpression in adult patients with well-differentiated NETs excluding neuroblastomas

Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma

noreply@esmo.org — Thu, 27 Aug 2026 07:08:00 +00:00

Findings from the COMBI-I study

FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

noreply@esmo.org — Wed, 26 Aug 2026 07:08:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-B15/EV-304 study

Thymus Radiation is Linked to Worse Outcomes in Patients with Non-Small Cell Lung Cancer

noreply@esmo.org — Wed, 26 Aug 2026 06:08:00 +00:00

Until recently, the thymus was thought to be of little use beyond puberty, but new research has shown that radiation to the organ is associated with worse outcomes in patients being treated for non-small cell lung cancer (NSCLC).

Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer

noreply@esmo.org — Tue, 25 Aug 2026 07:08:00 +00:00

Findings from the ENZAMET (ANZUP 1304) study

Metastatic Breast Cancer: ESMO Living Guideline

noreply@esmo.org — Mon, 24 Aug 2026 13:08:00 +00:00

Prepared by E de Azambuja and N Harbeck, the ESMO Metastatic Breast Cancer Living Guideline provides immediate access to the latest recommendations from the June 2026 CPG, with notable systemic treatment updates across several breast cancer subtypes, delivered through an interactive, mobile-friendly format

No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation

noreply@esmo.org — Mon, 24 Aug 2026 07:08:00 +00:00

Findings from the SKYSCRAPER-03 study

EMA Recommends Extension of Indications for Datopotamab Deruxtecan

noreply@esmo.org — Fri, 21 Aug 2026 07:08:00 +00:00

New indication concerns the first-line treatment of adult patients with unresectable or metastatic TNBC, who are not candidates for PD-(L)1 inhibitor therapy

High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma

noreply@esmo.org — Thu, 20 Aug 2026 07:08:00 +00:00

Findings from the MATRix/IELSG43 study

ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer

noreply@esmo.org — Wed, 19 Aug 2026 08:08:00 +00:00

Updated recommendations include daraxonrasib for second-line treatment of metastatic pancreatic cancer. This oral multi-selective RAS(ON) inhibitor has demonstrated significant improvements in overall survival and quality of life outcomes.

FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications

noreply@esmo.org — Wed, 19 Aug 2026 06:08:00 +00:00

Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies

Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors

noreply@esmo.org — Tue, 18 Aug 2026 08:08:00 +00:00

Findings from the LITESPARK-011 study

Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer

noreply@esmo.org — Mon, 17 Aug 2026 08:08:00 +00:00

Findings from the PSMAddition study

EMA Recommends Extension of Therapeutic Indications for Cetuximab

noreply@esmo.org — Fri, 14 Aug 2026 07:08:00 +00:00

New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib